123 related articles for article (PubMed ID: 15259445)
1. Laronidase opens door to treat other rare disorders.
Morrow T
Manag Care; 2004 Jun; 13(6):52-3. PubMed ID: 15259445
[No Abstract] [Full Text] [Related]
2. First treatment for rare enzyme disorder.
FDA Consum; 2003; 37(4):6. PubMed ID: 12971332
[No Abstract] [Full Text] [Related]
3. Alpha-L-iduronidase (laronidase; aldurazyme).
Med Lett Drugs Ther; 2003 Oct; 45(1168):88. PubMed ID: 14576624
[No Abstract] [Full Text] [Related]
4. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
Clarke LA; Wraith JE; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Sidman M; Kakkis ED; Cox GF
Pediatrics; 2009 Jan; 123(1):229-40. PubMed ID: 19117887
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
[TBL] [Abstract][Full Text] [Related]
6. [Hurler syndrome. Early diagnosis and successful enzyme replacement therapy: a new therapeutic approach. Case report].
Dupont C; El Hachem C; Harchaoui S; Ribault V; Amiour M; Guillot M; Maire I; Froissart R; Guffon-Fouilhoux N
Arch Pediatr; 2008 Jan; 15(1):45-9. PubMed ID: 18162380
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Beck M; Lane R; van der Ploeg A; Shapiro E; Xue Y; Kakkis ED; Guffon N
Pediatrics; 2007 Jul; 120(1):e37-46. PubMed ID: 17606547
[TBL] [Abstract][Full Text] [Related]
9. Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler-Scheie patient.
Soutar RL; Mercer J; Wraith JE
J Inherit Metab Dis; 2006 Aug; 29(4):590. PubMed ID: 16830264
[TBL] [Abstract][Full Text] [Related]
10. Mucopolysaccharidosis I under enzyme replacement therapy with laronidase--a mortality case with autopsy report.
Lin HY; Lin SP; Chuang CK; Chen MR; Chen BF; Wraith JE
J Inherit Metab Dis; 2005; 28(6):1146-8. PubMed ID: 16435211
[TBL] [Abstract][Full Text] [Related]
11. Combined enzyme replacement and haematopoietic stem cell transplantation in Hurler syndrome.
Bijarnia S; Shaw P; Vimpani A; Smith R; Pacey V; O'Grady H; Christodoulou J; Sillence D
J Paediatr Child Health; 2009; 45(7-8):469-72. PubMed ID: 19712183
[TBL] [Abstract][Full Text] [Related]
12. [Laronidase for treating post-surgical respiratory failure in a patient with type I mucopolysaccharidosis].
Vélez-Díaz-Pallarés M; Sánchez Cuervo M; Martínez-Pardo Casanova M; Bermejo Vicedo T
Farm Hosp; 2012; 36(1):55-6. PubMed ID: 21641259
[No Abstract] [Full Text] [Related]
13. Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I.
Anbu AT; Mercer J; Wraith JE
J Inherit Metab Dis; 2006 Feb; 29(1):230-1. PubMed ID: 16601901
[TBL] [Abstract][Full Text] [Related]
14. Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series.
Horovitz DD; Acosta AX; Giugliani R; Hlavatá A; Hlavatá K; Tchan MC; Lopes Barth A; Cardoso L; Embiruçu de Araújo Leão EK; Esposito AC; Kyosen SO; De Souza CF; Martins AM
Orphanet J Rare Dis; 2016 Apr; 11(1):51. PubMed ID: 27129473
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy in feline mucopolysaccharidosis I.
Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
[TBL] [Abstract][Full Text] [Related]
16. Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I.
Boy R; Schwartz IV; Krug BC; Santana-da-Silva LC; Steiner CE; Acosta AX; Ribeiro EM; Galera MF; Leivas PG; Braz M
J Med Ethics; 2011 Apr; 37(4):233-9. PubMed ID: 21266385
[TBL] [Abstract][Full Text] [Related]
17. Decreased corneal opacity and improved vision in a patient with mucopolysaccharidosis I (Hurler-Scheie) treated with enzyme replacement therapy (laronidase, Aldurazyme).
Cáceres-Marzal C; García-Reymundo M; Solana J; de Arévalo B; Vaquerizo J; Galán E
Am J Med Genet A; 2008 Jul; 146A(13):1768-70. PubMed ID: 18546328
[No Abstract] [Full Text] [Related]
18. Laronidase.
BioDrugs; 2002; 16(4):316-8. PubMed ID: 12196045
[TBL] [Abstract][Full Text] [Related]
19. Treatment of respiratory system (not just lung!) abnormalities in Mucopolysaccharidosis I.
Allen JL
J Pediatr; 2004 May; 144(5):561-2. PubMed ID: 15126984
[No Abstract] [Full Text] [Related]
20. Laronidase for cardiopulmonary disease in Hurler syndrome 12 years after bone marrow transplantation.
Valayannopoulos V; de Blic J; Mahlaoui N; Stos B; Jaubert F; Bonnet D; Fischer A; de Lonlay P
Pediatrics; 2010 Nov; 126(5):e1242-7. PubMed ID: 20974778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
